Lyra Therapeutics, Inc. LYRA 深 滬
已收盤 02-06 16:00:00 美东时间
1.82
+0.050
+2.82%
華盛通- 最 高1.90
- 今 開1.71
- 成交量 2.18万股
- 最 低 1.71
- 昨 收 1.77
- 總市值 323.03万
- 52周最高 37.50
- 市盈率 靜 --
- 換手率 1.23%
- 52周最低 1.60
- 委 比 86.92%
- 總股本 177.49万
- 歷史最高 1100.00
- 量 比 0.65
- 振 幅 10.73%
- 歷史最低 1.60
- 每 手 1
- 風險率 3.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lyra Therapeutics shares are trading lower after the company announced it received a Nasdaq delisting notification.
Lyra Therapeutics shares are trading lower after the company announced it recei...
02-07 05:18
Lyra Therapeutics shares are trading lower after the company announced it decided to suspend further development of LYR-210 and a workforce reduction.
Lyra Therapeutics shares are trading lower after the company announced it decid...
01-12 23:51
Lyra Therapeutics Decides To Suspend Further Development Of LYR-210, Its Lead Product Candidate For Chronic Rhinosinusitis, And Implement A Workforce Reduction Impacting Its Remaining 28 Employees
In June 2025, Lyra reported positive data from the ENLIGHTEN 2 Phase 3 trial of LYR-210, achieving statistically significant results for primary and key secondary endpoints in the treatment of CRS without nasal polyps.
01-12 20:06
Lyra Therapeutics Q3 EPS $(3.38) Beats $(5.25) Estimate, Sales $25.000K Miss $195.000K Estimate
Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(3.38) per share which beat the analyst consensus estimate of $(5.25) by 35.68 percent. This is a 62.44 percent increase over losses of $(9.00) per share from
2025-11-13 05:37
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Lyra Therapeutics plans a confirmatory Phase 3 trial for LYR-210 to treat chronic rhinosinusitis (CRS) without nasal polyps, advancing toward NDA submission. The company reported a net loss of $6.0 million in Q3 2025, with cash reserves of $22.1 million, sufficient to fund operations into Q3 2026. R&D expenses decreased by $1.9 million, while general and administrative expenses dropped by $1.7 million. LYR-210 aims to provide six months of anti-i...
2025-11-12 21:01
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 88.1% to $0.47 during Wednesd...
2025-10-15 20:09
Lyra Therapeutics Outlines Clinical Plan For LYR-210 Following FDA Meeting And Announces ENLIGHTEN 2 Late-Breaking Oral Presentation
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting
2025-10-06 19:08
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds
Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, congestion, and need for surgery.
2025-09-03 00:33
Lyra Therapeutics Receives Nasdaq Deficiency Letter
An update from Lyra Therapeutics ( ($LYRA) ) is now available. On August 20, 20...
2025-08-23 04:53
